INDICATIONS AND USAGE（适应症）

ERLEADA is indicated for the treatment of patients with:

Metastatic castration-sensitive prostate cancer (mCSPC)

Non-metastatic castration-resistant prostate cancer (nmCRPC)

DOSAGE（服用剂量）

The recommended dose of ERLEADA is 240 mg (four 60 mg tablets) administered orally once daily. Swallow the tablets whole. ERLEADA can be taken with or without food.

Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.

ADVERSE REACTIONS（不良反应）

Cerebrovascular and Ischemic Cardiovascular Events

Fractures

Falls

Seizure

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/d1cda4f7-cb33-46ea-b9ac-431f6452b1a5/spl-doc?hl=Apalutamide

Apalunixinformation